Edwards Lifesciences (EW) Other financing activities (2009 - 2026)

Edwards Lifesciences has reported Other financing activities for 18 years, with the latest figure at $53.8 million in Q2 2026.

• On a quarterly basis, Other financing activities fell 5.94% year-over-year to $53.8 million in Q2 2026; TTM through Jun 2026 was $189.7 million, a 11.46% increase from a year earlier, with the FY2025 full-year figure at $174.1 million, down 3.01% from the prior year.
• Other financing activities was $53.8 million for Q2 2026 at Edwards Lifesciences, down from $68.9 million in the prior quarter.
• The five-year high for Other financing activities was $68.9 million in Q1 2026, with the low at $27.5 million in Q4 2022.
• Average Other financing activities over 5 years is $44.0 million, with a median of $39.7 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Other financing activities soared 48.21% in 2024, then retreated 19.65% in 2025.
• Over 5 years, Other financing activities stood at $27.5 million in 2022, then grew by 20.73% to $33.2 million in 2023, then dropped by 13.86% to $28.6 million in 2024, then climbed by 12.94% to $32.3 million in 2025, then soared by 66.56% to $53.8 million in 2026.
• The last three Other financing activities figures came in at $53.8 million (Q2 2026), $68.9 million (Q1 2026), and $32.3 million (Q4 2025), per Business Quant data.